» Articles » PMID: 7401461

Uric Acid Saturation in Calcium Nephrolithiasis

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 1980 May 1
PMID 7401461
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperuricosuria appears to cause calcium oxalate nephrolithiasis by promoting the formation of monosodium urate or uric acid crystals, which either act as seed crystals for calcium oxalate or adsorb normally occurring macromolecular inhibitors of calcium oxalate crystallization. Both mechanisms require that hyperuricosuria cause excessive supersaturation of the urine, but this has not yet been studied under conditions of normal lifestyle. We have measured the saturation with respect to sodium hydrogen urate and the concentration of undissociated uric acid in the urine samples of 67 patients with calcium nephrolithiasis, who had idiopathic hypercalciuria, hyperuricosuria, both, or neither disorder. Patients with hyperuricosuria excreted urine that was supersaturated with respect to monosodium urate or undissociated uric acid more frequently than did other stone formers or normal subjects, and are therefore at a greater risk of forming a solid phase of monosodium urate or uric acid. Treatment measures that lowered uric acid excretion also lowered urine saturation, and this may be the reason that such treatment tends to prevent calcium stone recurrence.

Citing Articles

Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.

Anderegg M, Schietzel S, Bargagli M, Bally L, Faller N, Moor M Nat Med. 2025; 31(1):286-293.

PMID: 39747681 PMC: 11750721. DOI: 10.1038/s41591-024-03330-x.


Protein Intake and High Uric Acid Stone Risk.

Montgomery T, Nair H, Phadke M, Morhardt E, Ludvigson A, Motamedinia P Kidney Med. 2024; 6(9):100878.

PMID: 39279882 PMC: 11399574. DOI: 10.1016/j.xkme.2024.100878.


Associations between the platelet/high-density lipoprotein cholesterol ratio and likelihood of nephrolithiasis: a cross-sectional analysis in United States adults.

Ni J, Lv L, Wu P, Xu C Front Endocrinol (Lausanne). 2024; 15:1289553.

PMID: 38449847 PMC: 10914985. DOI: 10.3389/fendo.2024.1289553.


Efficacy of Theobromine and Its Metabolites in Reducing the Risk of Uric Acid Lithiasis.

Costa-Bauza A, Calvo P, Hernandez Y, Grases F Int J Mol Sci. 2023; 24(13).

PMID: 37446053 PMC: 10341826. DOI: 10.3390/ijms241310879.


Nephrolithiasis: A Red Flag for Cardiovascular Risk.

Gambaro A, Lombardi G, Caletti C, Ribichini F, Ferraro P, Gambaro G J Clin Med. 2022; 11(19).

PMID: 36233380 PMC: 9573143. DOI: 10.3390/jcm11195512.